Theodore Takata, MD
Clinical Cardiac Electrophysiology · Fort Worth, TXNPI 1801884382
Payments from drug & device makers
Across 835 payments — averaging $1619.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1M
- Boehringer Ingelheim$182K
- Lilly USA, LLC$69K
- Amgen$54K
- American Regent$11K
- Portola Pharmaceuticals, LLC$9K
- plus $17K from 22 others
What the payments were for
- Consulting fees$22,2906%
- Speaking & faculty fees$302,57376%
- Travel & lodging$56,87414%
- Food & beverage$13,9854%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 398 | $1,011,632 |
| Boehringer Ingelheim | 207 | $181,617 |
| Lilly USA, LLC | 99 | $68,713 |
| Amgen | 18 | $53,529 |
| American Regent | 2 | $11,100 |
| Portola Pharmaceuticals, LLC | 4 | $8,872 |
| Biosense Webster, Inc. | 21 | $7,698 |
| Philips North America LLC | 4 | $4,917 |
| Bayer | 8 | $1,220 |
| Altathera Pharmaceuticals LLC | 1 | $500 |
| Abbott | 11 | $456 |
| Novartis | 25 | $447 |
| Cordis US CORP. | 2 | $280 |
| E.r. Squibb & Sons, L.L.C. | 9 | $213 |
| Boston Scientific | 3 | $181 |
| Biotronik Inc. | 1 | $124 |
| Edwards Lifesciences | 1 | $108 |
| Sanofi-aventis U.S. LLC | 4 | $69 |
| Terumo Medical Corporation | 2 | $51 |
| AstraZeneca | 3 | $45 |
| Johnson & Johnson | 1 | $44 |
| Merck | 2 | $35 |
| Angiodynamics, Inc. | 2 | $30 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $27 |
| Pfizer | 2 | $26 |
| Heartflow, Inc. | 1 | $16 |
| Teleflex LLC | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$231,897
- PRADAXA$12,395
- Carto 3 System$7,249
- CartoSound$7,249
- EVERA MRI XT DR SURESCAN$5,901
- Spectranetics Undiv$4,800
- AURORA EV-ICD MRI SURESCAN$4,327
- Carto Smarttouch$1,064
- Sotalol Hydrochloride$500
- Heli-FX EndoAnchor System$200
- Micra$175
- AFFERA MAPPING SYSTEM$170
- Epsila EV$165
- PulseSelect$162
- Orsiro Mission$124
- Watchman$119
- Claria MRI$116
- AMPLATZER AMULET$112
- SAPIEN 3 Ultra RESILIA$108
- CG Future$106
How this compares
$1,351,981 in reported general payments places this provider in the 95th percentile of 233 clinical cardiac electrophysiology providers in Texas.
See all clinical cardiac electrophysiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 644 | $840,543 |
| JardianceEmpagliflozin | 226 | $280,746 |
| XareltoRivaroxaban | 97 | $124,448 |
| EntrestoSacubitril/Valsartan | 40 | $58,540 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 130 | $41,255 |
| PradaxaDabigatran Etexilate Mesylate | 45 | $11,837 |
| Repatha SureclickEvolocumab | 11 | $10,933 |
| Flecainide Acetate | 166 | $9,821 |
| SotalolSotalol Hcl | 341 | $8,381 |
| Dofetilide | 40 | $6,995 |
| Metoprolol Succinate | 315 | $6,005 |
| Amiodarone Hcl | 173 | $3,149 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 76 | $2,765 |
| Potassium Chloride | 63 | $1,498 |
| Colchicine | 11 | $1,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $26 | $840,543644 claims |
| Boehringer IngelheimJardiance, Pradaxa | $181,617 | $292,583271 claims |
| Johnson & JohnsonXarelto | $44 | $124,44897 claims |
| NovartisEntresto | $447 | $58,54040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 233 clinical cardiac electrophysiology providers in Texas.
Other clinical cardiac electrophysiology in Fort Worth
- Senthil ThambidoraiFort Worth$317K
- Sandeep KamathFort Worth$224K
- Aleem MughalFort Worth$212K
- Andrea NataleAustin$7.8M
- George ManoukianShenandoah$3.2M
- Rodney HortonAustin$2.5M
- Stanislav WeinerLongview$2.4M
- Michael DelaughterBedford$2.1M
- James DevillePlano$1.5M
- Robert CanbyAustin$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.